BONESUPPORT HOLDING AB (0RQO) AI Stock Analysis
BONESUPPORT HOLDING AB
(LSE:0RQO)
No summary available
BONESUPPORT HOLDING AB (0RQO) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- SEK 2.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 36.10K
- Price to Earnings (P/E)
- 78.7
- Beta (1Y)
- 0.73
- Revenue Growth
- 25.20%
- EPS Growth
- 79.34%
- Country
- UK
- Employees
- 171
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
BONESUPPORT HOLDING AB Business Overview & Revenue Model
Company Description
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationall...
BONESUPPORT HOLDING AB Earnings Call Summary
The call was strongly positive, driven by 38% constant-currency sales growth, improved operating margins, strong cash generation, continued U.S. CERAMENT G adoption, favorable CMS reimbursement changes, and positive SOLARIO results. The company also reaffirmed full-year growth guidance and reported progress on CERAMENT V and its spine strategy. Offsetting factors included higher commercial costs, a decline in U.S. gross margin, flat CERAMENT BVF sales, continued go-stop-go adoption patterns, and pending regulatory and clinical milestones.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
BONESUPPORT confirmed its previously communicated full-year outlook of sales growth between 33% and 36% in constant currency, based on continued commercial execution on existing baselines and “normalized commercial execution”; management does not expect CMS to have a material impact on revenue in Q4, but expects the ruling to help adoption and access over time and be an important topic in the coming quarters, with positive impact in the quarters to come. Management expects go-stop-go dynamics to continue in Q4 as well as next year, expects U.S. growth of 30%, 40% to require continued investment in the commercial organization, including accelerating administrator-focused hiring in the coming quarter as well as in the next year, and said it expects a formal FDA reply on CERAMENT V sometime in Q4 or Q1, followed by a couple of months between approval and starting sales.
BONESUPPORT HOLDING AB Peers Comparison
Overall Rating
SE:GETI.B67Neutral
SE:BACTI.B53Neutral
SE:INTEG.B50Neutral
SE:OSSD44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:GETI.B | 67Neutral | SEK 75.64B | 26.73 | 9.13% | 1.71% | -3.90% | 37.73% |
| SE:BACTI.B | 53Neutral | SEK 560.70M | 88.89 | 1.93% | ― | -0.51% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:INTEG.B | 50Neutral | SEK 243.48M | -5.77 | -20.71% | ― | 1.43% | 6.65% |
| SE:OSSD | 44Neutral | SEK 373.36M | -7.46 | ― | ― | -2.61% | -0.28% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0RQO | BONESUPPORT HOLDING AB | 325.00 | 113.20 | 53.45% | |
| SE:GETI.B | Getinge AB (UK) | 277.70 | 60.83 | 28.05% | |
| SE:BACTI.B | Bactiguard Holding AB | 16.00 | -1.00 | -5.88% | |
| SE:INTEG.B | Integrum AB Class B | 8.30 | 0.03 | 0.31% | |
| SE:PRO | Promimic AB | 9.45 | -4.55 | -32.50% | |
| SE:OSSD | OssDsign AB | 3.38 | -9.51 | -73.80% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.